Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of non-Hodgkin lymphoma that originates in T-cells, a type of white blood cell responsible for immune responses. First identified in the 1970s, PTCL encompasses a group of lymphomas that develop outside the …

The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the ...

2024年10月31日 · The treatment of common nodal peripheral T-cell lymphomas (PTCLs), including PTCL, not otherwise specified (PTCL, NOS), anaplastic large-cell lymphomas, and T-follicular helper lymphomas, is evolving.

2024年6月1日 · In this review, we provide a comprehensive overview of the progress in developing clinical prognostic indices for PTCL and describe the broad therapeutic landscape, emphasizing novel targetable pathways that have entered early phase clinical studies.

2024年1月4日 · This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development.

2022年3月1日 · Peripheral T-cell Lymphomas (PTCL) are a heterogenous group of aggressive non-Hodgkin lymphomas that are far less sensitive to chemotherapy than their B-cell counterparts. Despite their poor prognosis, they are treated similarly to most aggressive B-cell lymphomas, heavily relying on CHOP or CHOP-like combination chemotherapy irrespective of ...

Indians, PTCL, NOS is the most common PTCL subtype, accounting for ≈30% of PTCL, and is twice as prevalent as either angioimmunoblastic T-cell lymphomas (AITL) or anaplastic large

PTCLs are uncommon and heterogeneous malignant lymphoproliferative disorders that originate from post-thymic (peripheral) T cells or mature natural killer (NK) cells. They represent 10%–15% of all non-Hodgkin's lymphomas.

2011年6月23日 · Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies.

Utilizing a "3 signal" model, we will review new-and old-therapeutic targets that are relevant for the more common nodal PTCL subtypes. Download scientific diagram | PTCLs are dependent upon...